MétaCan
Menu
← Back to cohort

Identifying opportunities to improve quality of cancer care: An evaluation of the use of diagnostic imaging in women curatively treated for early breast cancer (EBC).

2016· article· en· W2892206270 on OpenAlexaffabout
Katherine Enright, Tejas Desai, Rinku Sutradhar, Alejandro Gonzalez, Melanie Powis, Nathan Taback, Christopher M. Booth, Maureen Trudeau, Monika K. Krzyzanowska

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsSunnybrook Health Science CentreQueen's UniversityInstitute for Clinical Evaluative SciencesPrincess Margaret Cancer CentreHealth Sciences CentreCredit Valley HospitalUniversity Health NetworkUniversity of TorontoTrillium Health Centre
Fundersnot available
KeywordsMedicineBreast cancerPopulationMedical imagingCancerCancer registryStage (stratigraphy)ComorbidityMedical recordRadiologyEmergency medicineInternal medicine

Abstract

fetched live from OpenAlex

6603 Background: The overuse of imaging scans to detect recurrence in curatively treated EBC patients was recently identified as one of ASCO’s top five opportunities to improve the quality of cancer care. We undertook a population-level assessment of the current practice of imaging in women treated for EBC. Methods: EBC patients diagnosed in Ontario, Canada between 01/2006 –and 12/2010 were identified from the Ontario Cancer Registry. Patient records were linked deterministically to provincial healthcare databases to provide comprehensive follow-up. We identified any advanced imaging scans (AIS) (computed tomography, bone scans) and basic imaging scans (BIS) during the first year after completion of curative treatment. Descriptive analyses were used to assess the impact of patient and provider characteristics on the likelihood of having AIS. Results: Of the 30,006 EBC patients included, 9,186 (30.6 %) had AIS in year one (Table). In patients with AIS, the median number of scans was 2.5(IQR1-3). Older age, higher stage, comorbidity, chemotherapy (CT) exposure and having had staging investigations increased the likelihood of AIS (P < 0.001). The majority of year one scans were ordered by medical oncologists (38%) followed by primary care physicians (23%), surgeons (13%) and emergency room physicians (7%). Conclusions: While imaging is common in follow-up for EBC patients and appropriate for symptom driven investigation, the high rate of AIS use is an actionable target for quality improvement. Use of BIS and AIS in first year of follow up for EBC. Advanced N=9,186 (30.6%) Basic N=8,401 (28.0%) No Imaging N=12,419 (41.4%) Age Median (IQR) 60 (50-71) 60 (49-70) 61 (51-70) Stage 1 3,127 (34.0%) 4,018 (47.8%) 6,123 (49.3%) 2 3,978 (43.3%) 3,421 (40.7%) 4,888 (39.4%) 3 2,081 (22.7%) 962 (11.5%) 1,408 (11.3%) Comorbidity 0 8,333 (90.7%) 7,780 (92.6%) 11,695 (94.2%) 1 268 (2.9%) 183 (2.2%) 203 (1.6%) 2+ 585 (6.4%) 438 (5.2%) 521 (4.2%) Treatment Adjuvant CT 4,392 (47.8%) 3,441 (41.0%) 4,529 (36.5%) Neoadjuvant CT 743 (8.1%) 303 (3.6%) 533 (4.3%) No CT 4,051 (44.1%) 4,657 (55.4%) 7,357 (59.2%) Staging Scans 6,650 (72.4%) 5,237 (62.3%) 7,261 (58.5%)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.010
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.270
Threshold uncertainty score0.537

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.010
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.341
GPT teacher head0.521
Teacher spread0.181 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicBreast Cancer Treatment Studies→French-language works237,207→